Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma

Histopathology

Volumn 66, Issue 6, 2015, Pages 901-904

  Pinto, Andre ^a   Signoretti, Sabina ^a   Hirsch, Michelle S ^a   Barletta, Justine A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE V600E; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN;

ADULT; ANTIGEN RETRIEVAL; CHROMATIN; CLINICAL ARTICLE; CYTOPLASM; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE MUTATION; GENOTYPE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY ADENOMA; KIDNEY CARCINOMA; LETTER; MASS SPECTROMETRY; METANEPHRIC ADENOMA; MIDDLE AGED; MUTATIONAL ANALYSIS; NEPHROBLASTOMA; ONCOCYTOMA; PRIORITY JOURNAL; PYROSEQUENCING; TISSUE MICROARRAY; TISSUE SECTION; TUMOR VOLUME; ADENOMA; CARCINOMA, RENAL CELL; GENETICS; KIDNEY NEOPLASMS; MUTATION;

ADENOMA; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84927046631     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12509     Document Type: Letter

References (9)

1. Davis CJ Jr, Barton JH, Sesterhenn IA, Mostofi FK. Metanephric adenoma. Clinicopathological study of fifty patients. Am. J. Surg. Pathol. 1995; 19; 1101-1114.
2. Mantoan Padilha M, Billis A, Allende D, Zhou M, Magi-Galluzzi C. Metanephric adenoma and solid variant of papillary renal cell carcinoma: common and distinctive features. Histopathology 2013; 62; 941-953.
3. Masuda A, Kamai T, Mizuno T et al. Renal metanephric adenoma mimicking papillary renal cell carcinoma on computed tomography: a case report. Urol. Int. 2013; 90; 369-372.
4. Olgac S, Hutchinson B, Tickoo SK, Reuter VE. Alpha-methylacyl-coa racemase as a marker in the differential diagnosis of metanephric adenoma. Mod. Pathol. 2006; 19; 218-224.
5. Choueiri TK, Cheville J, Palescandolo E et al. BRAF mutations in metanephric adenoma of the kidney. Eur. Urol. 2012; 62; 917-922.
6. Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP. Comparison of 2 monoclonal antibodies for immunohistochemical detection of braf v600e mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum. Pathol. 2013; 44; 2563-2570.
7. Ghossein RA, Katabi N, Fagin JA. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease. J. Clin. Endocrinol. Metab. 2013; 98; E1414-E1421.
8. Pearlstein MV, Zedek D, Ollila DW et al. Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma. J. Cutan. Pathol. 2014; Epub ahead of print.
9. Miao J, Kusafuka T, Fukuzawa M. Hotspot mutations of BRAF gene are not assoicated with pediatric solid neoplasms. Oncol. Rep. 2004; 12; 1269-1272.